The success of endosseous implants in human immunodeficiency virus-positive patients receiving antiretroviral therapy A pilot study


Autoria(s): OLIVEIRA, Marcio A.; GALLOTTINI, Marina; PALLOS, Debora; MALUF, Paulo S. Z.; JABLONKA, Fernando; ORTEGA, Karem L.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2011

Resumo

Background. In a pilot study, the authors aimed to determine the success rate of dental implants placed in patients who were positive for human immunodeficiency virus (HIV) and were receiving different regimens of highly active anti-retroviral therapy (HAART). They considered patients` levels of cluster of differentiation (CD) 4(+) cells and viral load, and they attempted to verify whether patients with baseline biochemical signs of bone mineral density loss could experience osseointegration impairment. Materials and Methods. One of the authors, a dentist, placed dental implants in the posterior mandibles of 40 volunteers, divided into three groups: one composed of HIV-positive patients receiving protease inhibitor (PI)-based HAART; a second composed of HIV-positive patients receiving nonnucleoside reverse transcriptase inhibitor based HAART (without PI); and a control group composed of HIV-negative participants. The authors assessed pen-implant health six and 12 months after implant loading. They analyzed the success of the implants in relation to CD4(+) cell counts, viral load and baseline pyridinoline and deoxypyridinoline values. Results. The authors followed 59 implants for 12 months after loading. Higher baseline levels of pyridinoline and deoxypyridinoline found in HIV-positive participants did not interfere with osseointegration after 12 months of follow-up. Average pen-implant bone loss after 12 months was 0.49 millimeters in group 1, 0.47 mm in group 2, and 0.55 mm in the control group. Conclusions. The placement of dental implants in HIV-positive patients is a reasonable treatment option, regardless of CD4(+) cell count, viral load levels and type of antiretroviral therapy. Longer, follow-up periods are necessary to ascertain the predictability of the long-term success of dental implants in these patients. Clinical Implications. Limited published scientific evidence is available to guide clinicians in regard to possible increased risks associated with dental implant placement in HIV-positive patients.

Sao Paulo Research Foundation FAPESP[60239-0/2006]

Identificador

JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, v.142, n.9, p.1010-1016, 2011

0002-8177

http://producao.usp.br/handle/BDPI/25661

http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&UT=000294973000010&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord

Idioma(s)

eng

Publicador

AMER DENTAL ASSOC

Relação

Journal of the American Dental Association

Direitos

restrictedAccess

Copyright AMER DENTAL ASSOC

Palavras-Chave #Human immunodeficiency virus #AIDS #highly active antiretroviral therapy #dental implants #pyridinoline #deoxypyridinoline #BRANEMARK IMPLANT #CONTROLLED-TRIAL #HIV #DISEASE #AIDS #Dentistry, Oral Surgery & Medicine
Tipo

article

original article

publishedVersion